Thermo Fisher Scientific
2Q Revenues: $6.3 billion(+4%)
2Q Earnings: $1.1 billion (+49%)
YTD Revenues: $12.4 billion (+4%)
YTD Earnings: $1.9 billion (+45%)
Comments: The Life Sciences Solutions Segment revenue was up 9% to $1.7 billion in the quarter. Analytical Instruments Segment revenue grew 1% to $1.3 billion. Specialty Diagnostics Segment revenue increased 1% to $0.94 billion. Laboratory Products and Services Segment revenue grew 3% to $2.6 billion. Reported results in 2019 and 2018 include restructuring and other costs, consisting principally of severance, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations. Reported results in 2019 include a $505 million gain on the sale of the Anatomical Pathology business and $6 million of charges for impairment of acquired technology in development.